Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety, tolerability, and acceptability of <i>Lactobacillus crispatus</i> CTV-05 (LACTIN-V) in pregnant women at high-risk of preterm birth.

Beneficial microbes·2023

Same author

A dynamical model of oncotripsy by mechanical cell fatigue: selective cancer cell ablation by low-intensity pulsed ultrasound.

Proceedings. Mathematical, physical, and engineering sciences·2020

Same author

Methods for Use of Peptide-MHCTetramers in Tumor Immunology.

Methods in molecular medicine·2012

Same author

Fractal dimension evaluation of cone beam computed tomography in patients with bisphosphonate-associated osteonecrosis.

Dento maxillo facial radiology·2011

Same author

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.

Leukemia·2011

Same author

Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus.

Mucosal immunology·2011

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Tissue plasminogen activator and glaucoma drainage implants.

P A Sidoti¹, E N Morinelli, D K Heuer

¹Department of Ophthaimology, University of Southern California School of Medicine, and the Doheny Eye Institute, Los Angeles, California, U.S.A.

Journal of Glaucoma

|November 19, 2009

Summary

This summary is machine-generated.

Tissue plasminogen activator effectively resolves glaucoma drainage tube obstruction caused by blood or fibrin clots. This treatment offers a less invasive alternative to surgery for managing elevated intraocular pressure post-glaucoma surgery.

More Related Videos

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Related Experiment Videos

Last Updated: Jun 18, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Area of Science:

Ophthalmology
Glaucoma Management
Surgical Innovation

Background:

Glaucoma drainage implants are crucial for managing intraocular pressure.
Implant tube occlusion by blood or fibrin clots is a common postoperative complication.
Neovascular glaucoma presents unique challenges for drainage device patency.

Purpose of the Study:

To describe the use of tissue plasminogen activator for glaucoma drainage tube obstruction.
To evaluate the efficacy of intracameral tissue plasminogen activator in resolving tube blockages.
To present a less invasive management option for early postoperative complications.

Main Methods:

Case report of two patients with neovascular glaucoma and drainage tube obstruction.
Treatment involved intracameral injection of tissue plasminogen activator.
Observation of intraocular pressure, bleb formation, and tube patency.

Main Results:

Successful resolution of tube obstruction in both reported cases.
Spontaneous reduction of intraocular pressure following treatment.
Facilitation of bleb formation post-obstruction resolution.

Conclusions:

Intracameral tissue plasminogen activator can effectively treat glaucoma drainage tube obstruction.
This method is beneficial even when clots are not overtly visible.
Consider tissue plasminogen activator before resorting to more invasive surgical revisions.